Particle radiotherapy in the era of radioimmunotherapy

Zhou, Zihan; Guan, Bingjie; Hu, Xia; Zheng, Rong; Xu, Benhua

doi:10.1016/j.canlet.2023.216268

Cited by 10 publications

(5 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radiation therapy (RT) stands as a cornerstone among contemporary cancer treatment modalities, with over 70% of tumor patients undergoing RT intervention (Zhou et al., 2023 ). The fundamental mechanism underlying RT's efficacy primarily revolves around direct DNA damage and its impact on tumor cells, mediated by the generation of ROS (Zou et al., 2017 ).…”

Section: Application Of Aging In Clinical Tumor Therapymentioning

confidence: 99%

The impact of the senescent microenvironment on tumorigenesis: Insights for cancer therapy

Zhang,

Shi

et al. 2024

Aging Cell

View full text Add to dashboard Cite

The growing global burden of cancer, especially among people aged 60 years and over, has become a key public health issue. This trend suggests the need for a deeper understanding of the various cancer types in order to develop universally effective treatments. A prospective area of research involves elucidating the interplay between the senescent microenvironment and tumor genesis. Currently, most oncology research focuses on adulthood and tends to ignore the potential role of senescent individuals on tumor progression. Senescent cells produce a senescence‐associated secretory phenotype (SASP) that has a dual role in the tumor microenvironment (TME). While SASP components can remodel the TME and thus hinder tumor cell proliferation, they can also promote tumorigenesis and progression via pro‐inflammatory and pro‐proliferative mechanisms. To address this gap, our review seeks to investigate the influence of senescent microenvironment changes on tumor development and their potential implications for cancer therapies.

show abstract

Section: Application Of Aging In Clinical Tumor Therapymentioning

confidence: 99%

The impact of the senescent microenvironment on tumorigenesis: Insights for cancer therapy

Zhang,

Shi

et al. 2024

Aging Cell

View full text Add to dashboard Cite

show abstract

“…Since heavy-ion irradiation does not impair healthy tissues beneath cancer due to its unique property named spread-out Bragg peak, as described above, it is plausible that the immune system remains healthy in response to the cancer fragments or particles generated by CIRT. Indeed, ICRT-irradiated cancer cells harbor robust cytotoxic lymphocytes such as CD8 + T cells and NK cells, which are rarely observed in non-irradiated cancer cells [ 63 , 64 ]. However, the underlying mechanisms are not fully understood.…”

Section: Cirt Activation Of Anti-cancer Immunitymentioning

confidence: 99%

“…The activation of these pathways is linked to the activation of anti-cancer adaptive immunity. Many constructive review articles provide detailed narrations of breakthrough findings [ 64 , 65 , 66 ].…”

Section: Cirt Activation Of Anti-cancer Immunitymentioning

confidence: 99%

Carbon Ion Irradiation Activates Anti-Cancer Immunity

Sudo,

Tsutsui,

Fujimoto

2024

IJMS

View full text Add to dashboard Cite

Carbon ion beams have the unique property of higher linear energy transfer, which causes clustered damage of DNA, impacting the cell repair system. This sometimes triggers apoptosis and the release in the cytoplasm of damaged DNA, leading to type I interferon (IFN) secretion via the activation of the cyclic GMP–AMP synthase-stimulator of interferon genes pathway. Dendritic cells phagocytize dead cancer cells and damaged DNA derived from injured cancer cells, which together activate dendritic cells to present cancer-derived antigens to antigen-specific T cells in the lymph nodes. Thus, carbon ion radiation therapy (CIRT) activates anti-cancer immunity. However, cancer is protected by the tumor microenvironment (TME), which consists of pro-cancerous immune cells, such as regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages. The TME is too robust to be destroyed by the CIRT-mediated anti-cancer immunity. Various modalities targeting regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages have been developed. Preclinical studies have shown that CIRT-mediated anti-cancer immunity exerts its effects in the presence of these modalities. In this review article, we provide an overview of CIRT-mediated anti-cancer immunity, with a particular focus on recently identified means of targeting the TME.

show abstract

“…Radiotherapy refers to the use of various types of radiation to damage the genetic material of tumor cells, thereby inhibiting and killing these cells. 40 Currently, there are numerous clinical studies exploring the combination of radiotherapy with ICIs in various cancers such as lung cancer, renal cancer, bladder cancer, and more. Positive clinical outcomes have been observed in terms of DCR, ORR, and patient survival.…”

Section: Immunotherapy Checkpoint Inhibitors Combined With Radiotherapymentioning

confidence: 99%

Research progress and future directions of immune checkpoint inhibitor combination therapy in advanced gastric cancer

He,

Ma,

et al. 2024

Ther Adv Med Oncol

View full text Add to dashboard Cite

In recent years, with the continuous development of molecular immunology, immune checkpoint inhibitors (ICIs) have also been widely used in the treatment of gastric cancer, but they still face some challenges: The first is that only some people can benefit, the second is the treatment-related adverse events (TRAEs) that occur during treatment, and the third is the emergence of varying degrees of drug resistance with long-term use. How to overcome these challenges, combined therapy based on ICIs has become one of the important strategies. This article summarizes the clinical application of ICIs combined with chemotherapy, targeted therapy, radiotherapy, photodynamic therapy, thermotherapy, immune adjuvant, and dual immunotherapy and discusses the mechanism, and also summarizes the advantages and disadvantages of the current combination modalities and the potential research value. The aim of this study is to provide more and more optimized combination regimen for ICI combined therapy in patients with advanced gastric cancer and to provide reference for clinical and scientific research.

show abstract

Particle radiotherapy in the era of radioimmunotherapy

Cited by 10 publications

References 94 publications

The impact of the senescent microenvironment on tumorigenesis: Insights for cancer therapy

The impact of the senescent microenvironment on tumorigenesis: Insights for cancer therapy

Carbon Ion Irradiation Activates Anti-Cancer Immunity

Research progress and future directions of immune checkpoint inhibitor combination therapy in advanced gastric cancer

Contact Info

Product

Resources

About